High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.
作者信息
Jolles S
出版信息
Clin Exp Immunol. 2002 Sep;129(3):385-9. doi: 10.1046/j.1365-2249.2002.01967.x.
Abstract
摘要
相似文献
1
High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.
Clin Exp Immunol. 2002 Sep;129(3):385-9. doi: 10.1046/j.1365-2249.2002.01967.x.
2
High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
J Am Acad Dermatol. 2007 Jun;56(6):960-7. doi: 10.1016/j.jaad.2006.06.029. Epub 2007 Mar 21.
3
Dermatological uses of high-dose intravenous immunoglobulin.
Arch Dermatol. 1998 Jan;134(1):80-6. doi: 10.1001/archderm.134.1.80.
4
Treatment Update of Autoimmune Blistering Diseases.
Dermatol Clin. 2019 Apr;37(2):215-228. doi: 10.1016/j.det.2018.12.003. Epub 2019 Feb 14.
5
Autoimmune bullous diseases: diagnosis and management.
Dermatol Nurs. 2006 Feb;18(1):20-5.
6
A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders.
Clin Exp Dermatol. 2001 Mar;26(2):127-31. doi: 10.1046/j.1365-2230.2001.00779.x.
7
High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases.
Br J Dermatol. 1999 May;140(5):865-74. doi: 10.1046/j.1365-2133.1999.02817.x.
8
Mucocutaneous features of autoimmune blistering diseases.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Nov;84(5):517-34. doi: 10.1016/s1079-2104(97)90269-9.
9
A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
Exp Dermatol. 2023 Jul;32(7):934-944. doi: 10.1111/exd.14829. Epub 2023 May 7.
10
New immunomodulating drugs in autoimmune blistering diseases.
Dermatol Clin. 2001 Oct;19(4):637-48, viii. doi: 10.1016/s0733-8635(05)70305-3.
引用本文的文献
1
Intravenous Immunoglobulin: Revisited - My Experience.
Indian J Dermatol. 2021 May-Jun;66(3):329. doi: 10.4103/ijd.IJD_559_17.
2
Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model FcγRIIA and FcαRI.
Front Immunol. 2021 Jun 10;12:700429. doi: 10.3389/fimmu.2021.700429. eCollection 2021.
3
Biologics in dermatology: an integrated review.
Indian J Dermatol. 2014 Sep;59(5):425-41. doi: 10.4103/0019-5154.139859.
4
The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis.
Int J Rheumatol. 2011;2011:829751. doi: 10.1155/2011/829751. Epub 2011 Nov 2.
5
High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.
Clin Rev Allergy Immunol. 2010 Apr;38(2-3):186-95. doi: 10.1007/s12016-009-8153-y.
6
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.
J Clin Immunol. 2007 May;27(3):233-45. doi: 10.1007/s10875-007-9088-9. Epub 2007 Mar 11.
7
Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report.
J Transl Med. 2006 Oct 24;4:43. doi: 10.1186/1479-5876-4-43.
8
Clinical uses of intravenous immunoglobulin.
Clin Exp Immunol. 2005 Oct;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x.
9
Autoimmune bullous diseases: ocular manifestations and management.
Drugs. 2005;65(13):1767-79. doi: 10.2165/00003495-200565130-00003.
本文引用的文献
1
Immunomodulatory action of intravenous immunoglobulin.
Immunology. 2002 Dec;107(4):387-93. doi: 10.1046/j.1365-2567.2002.01545.x.
2
Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin.
Clin Exp Immunol. 2002 Sep;129(3):533-40. doi: 10.1046/j.1365-2249.2002.01942.x.
3
Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Eur J Dermatol. 2002 Mar-Apr;12(2):174-8.
4
Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
Clin Immunol. 2002 Jan;102(1):59-67. doi: 10.1006/clim.2001.5150.
5
Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin.
J Am Acad Dermatol. 2002 Jan;46(1):116-22. doi: 10.1067/mjd.2002.117860.
6
Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.
J Am Acad Dermatol. 2002 Jan;46(1):42-9. doi: 10.1067/mjd.2002.116338.
7
Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
J Am Acad Dermatol. 2001 Nov;45(5):679-90. doi: 10.1067/mjd.2001.116339.
8
Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy.
Arch Dermatol. 2001 Sep;137(9):1181-9. doi: 10.1001/archderm.137.9.1181.
9
Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.
Clin Exp Immunol. 2001 Sep;125(3):492-8. doi: 10.1046/j.1365-2249.2001.01637.x.
10
Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy.
Ophthalmology. 2000 Aug;107(8):1524-8. doi: 10.1016/s0161-6420(00)00245-1.
Zotero 插件